Saeko Ota-Kuwahara

Kyoto, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Non-infectious fever defines a subgroup of patients with poorer survival outcomes in high-risk myelodysplastic syndrome.

Non-infectious fever defines a subgroup of patients with poorer survival outcomes in high-risk myelodysplastic syndrome.

Journal: British journal of haematology

Published: February 02, 2026

Real-world data of polatuzumab vedotin with bendamustine and rituximab for Japanese relapsed and refractory DLBCL: a multicenter retrospective study.

Real-world data of polatuzumab vedotin with bendamustine and rituximab for Japanese relapsed and refractory DLBCL: a multicenter retrospective study.

Journal: Leukemia & lymphoma

Published: March 26, 2025

Clinical impacts of severe thrombocytopenia in the first cycle of azacitidine monotherapy and cytogenetics in patients with myelodysplastic syndrome: The Kyoto Conditional Survival Scoring System.

Clinical impacts of severe thrombocytopenia in the first cycle of azacitidine monotherapy and cytogenetics in patients with myelodysplastic syndrome: The Kyoto Conditional Survival Scoring System.

Journal: Oncology letters

Published: August 01, 2023

Real-world practice-based prognostic model for higher-risk myelodysplastic syndromes treated with azacitidine monotherapy: The Kyoto prognostic scoring system.

Real-world practice-based prognostic model for higher-risk myelodysplastic syndromes treated with azacitidine monotherapy: The Kyoto prognostic scoring system.

Journal: International journal of hematology

Published: April 04, 2023

Tumour-derived exosomes promote the induction of monocytic myeloid-derived suppressor cells from peripheral blood mononuclear cells by delivering miR-106a-5p and miR-146a-5p in multiple myeloma.

Tumour-derived exosomes promote the induction of monocytic myeloid-derived suppressor cells from peripheral blood mononuclear cells by delivering miR-106a-5p and miR-146a-5p in multiple myeloma.

Journal: British journal of haematology

Published: March 21, 2023

EWSR1 overexpression is a pro-oncogenic event in multiple myeloma.

EWSR1 overexpression is a pro-oncogenic event in multiple myeloma.

Journal: International journal of hematology

Published: July 06, 2020

Aberrant BUB1 Overexpression Promotes Mitotic Segregation Errors and Chromosomal Instability in Multiple Myeloma.

Aberrant BUB1 Overexpression Promotes Mitotic Segregation Errors and Chromosomal Instability in Multiple Myeloma.

Journal: Cancers

Published: July 02, 2020

Toward further simplification of elotuzumab therapy by subcutaneous administration.

Toward further simplification of elotuzumab therapy by subcutaneous administration.

Journal: International journal of hematology

Published: May 27, 2020

Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma.

Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma.

Journal: British journal of haematology

Published: February 22, 2020

Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib.

Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib.

Journal: Infection and drug resistance

Published: February 09, 2020

Serine-227 in the N-terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma.

Serine-227 in the N-terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma.

Journal: Cancer medicine

Published: January 29, 2020

Tumor-specific transcript variants of cyclin D1 in mantle cell lymphoma and multiple myeloma with chromosome 11q13 abnormalities.

Tumor-specific transcript variants of cyclin D1 in mantle cell lymphoma and multiple myeloma with chromosome 11q13 abnormalities.

Journal: Experimental hematology

Published: January 19, 2020

Showing 1-12 of 18

Last Updated: 09/26/2026